Eledon Q4 net loss $44.6M; cash runway extended; tegoprubart used in pig kidney transplant

Eledon Pharmaceuticals, Inc.

Q4 2024 net loss $44.6M ($0.64/shr) vs $30.1M ($1.00/shr) in Q4 2023; includes non-cash warrant loss $20.9M.
FY 2024 net loss $36.2M vs $116.5M in 2023; excluding warrant changes, net loss $67.1M vs $40.3M.
Cash $140.2M at Dec 31, 2024; $85M oversubscribed offering extends runway to end of 2026.
Tegoprubart used in second genetically modified pig kidney transplant (Jan 25, 2025) at Mass General; patient off dialysis.
Positive initial data on islet transplant recipients; insulin independence without tacrolimus; topline Ph2 BESTOW due Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.